Managed Care Watch
Company findings / Initial collection

CVS Health / Aetna

Public spending, contract decisions, workforce disclosures and executive leadership.

Download research workbook
Recent company updates

New developments.

CVS Health / Aetna / Quality ratings

Published 2026-10-08 · Added 2026-10-09

Event date: 2026-10-08

Aetna reports more than 69% of members in contracts with four-star-or-higher 2027 ratings

Aetna reported that more than 69% of its Medicare Advantage members are in plans rated at least four stars for 2027. Its calculation uses CMS ratings released October 8 and September 2026 MA and MA-PD enrollment; individual ratings vary.

Why it matters: This is a company enrollment-based summary, not the percentage of contracts and not a forecast of actual 2027 membership. Members should examine their own contract and care-access measures rather than relying on the overall company percentage.

Company summary of published CMS ratings; enrollment basis disclosed

CVS Health / Aetna: source

Aetna findings
CVS Health / Aetna

Published 2026-10-03 · Added 2026-10-07

Event date: 2026-10-03

Aetna expands HMO focus and chronic-condition plans for 2027

Aetna says its 2027 Medicare Advantage prescription drug plans will be offered in 41 states plus Washington, D.C. It describes expanding Prime HMO offerings in selected markets and chronic-condition special needs plans into six additional states, reaching 25 states.

Why it matters: Availability is not enrollment or proof of adequate access. Local provider networks, referral requirements, drug coverage and annual notices of change are essential for evaluating the member impact.

Company announcement; future portfolio

CVS Health / Aetna: source

Aetna findings

Review completed October 13, 2026. Added Humana's announced CenterWell clinic joint venture with BlackRock. The transaction is pending regulatory approval and the stated $2.8 billion is the value of WCAS's equity stake, not proceeds to Humana or a fine.

CMS and managed care news archive
Analysis

What the documented record shows.

Coding integrity affects public spending

The $117.7 million settlement resolves allegations concerning Medicare Advantage diagnoses. It concerns payment accuracy; it does not by itself establish that each affected member was denied care. Primary source

Contract outcomes can change the member’s plan

Aetna’s Kansas contract ended in 2024. Procurement replacement should be distinguished from regulatory termination for misconduct, which these sources do not establish. Primary source

Pay and restructuring coexist

Company disclosures show executive compensation and workforce restructuring during the period. Their coexistence supports examination of resource allocation but does not establish that pay caused layoffs or care failures.

01 / Financial accountability

Fines, settlements and audit findings.

Amounts retain their original category and payment status. There is no combined “fines paid” total.

2020-10-28 · AetnaSettlement / Health information privacy$1,000,000

HHS reports paid

HIPAA settlement addressing three privacy breaches.

Primary source

2025-12-02 · CVS PharmacySettlement / Federal health programs / pharmacy$37,760,000

Settlement approved; payment not independently confirmed

False Claims Act resolution concerning insulin pen dispensing and billing.

Retail pharmacy action, not an Aetna insurance fine.

Primary source

2026-03-10 · AetnaSettlement / Medicare Advantage$117,700,000

Agreed; payment not independently confirmed

DOJ alleged inaccurate diagnoses and failure to withdraw unsupported codes increased Medicare payments.

Includes $106.2 million for 2015 chart reviews and $11.5 million for morbid-obesity coding in 2018–2023. No determination of liability.

Primary source

2026-07-14 · Caremark / ZincProposed nonmonetary consent / Pharmacy benefit managementNot quantified

Proposed consent announced; final disposition not verified

FTC announced proposed reforms to PBM compensation, transparency and access.

Projected future savings are not fines paid and are excluded from financial amounts.

Primary source

02 / Public contracts

Contract awards, losses and exits.

Intent to award is identified separately from final selection and an operational contract. Announcement dates may differ from service start dates.

DateState / programOutcome / statusRecord
2024Kansas
KanCare		Lost / not renewed
Aetna coverage ended 2024-12-31		State selected other plans for 2025; Aetna notified members of contract end.
Primary source
2023-06-08Oklahoma
SoonerSelect		Award
Award announced; launch expected April 2024 in notice		Medical managed care selection, subject to CMS approval at announcement.
Primary source
03 / Workforce

Reductions and staffing questions.

Costs below are disclosed accounting charges. They are not fines, employee counts or proof of a care impact.

YearDisclosed costWhat is establishedSource
2023$344,000,000Severance and employee-related workforce optimization costs, within a broader $507 million restructuring charge. Not an Aetna-only job count.Primary source
2024$293,000,000Corporate workforce optimization costs including severance and employee-related costs. Broader restructuring also included store and asset impairments.Primary source
Layoffs followed by the same job postings: not yet verified.

Matching requires the employing entity, duties, location, job title, requisition and dated layoff notice and advertisement. General hiring after layoffs does not establish that the same positions were replaced.

04 / Executive leadership

Pay, benefits and turnover.

2025 named executive compensation

Reported SEC summary compensation totals include grant-date stock and option values. These are not cash take-home pay. Roles reflect the 2025 disclosure; partial-year and former executives are included.

Executive / disclosed roleSalaryAll other compensationReported total
David Joyner
CEO		$1,500,000$453,609$21,214,084
Brian Newman
CFO		$696,970$161,599$9,420,508
Tilak Mandadi
EVP		$1,000,000$416,755$10,977,716
Steve Nelson
Aetna president		$1,000,000$349,201$11,587,110
Prem Shah
EVP		$1,100,000$266,297$13,379,210
Thomas Cowhey
Former CFO		$420,833$791,235$6,715,138

2026 proxy: Summary Compensation Table. Full components are in the workbook.

CEO compensation history collected so far

YearExecutiveReported totalContext
2022Karen Lynch$21,317,055
2023Karen Lynch$21,615,034
2024Karen Lynch$23,431,466Former CEO from October 2024
2024David Joyner$17,808,792CEO from October 2024; includes compensation in prior role
2025David Joyner$21,214,084

Earlier-year extraction is incomplete. Missing years are not zero compensation; see research gaps below.

Selected benefits and other compensation components

Executive2025 componentAmount
David JoynerAll other compensation, detailed extraction pending$453,609

Components are already included in all other compensation; do not add them to reported total pay. Coverage of detailed benefits is partial.

Documented leadership changes

Effective / announcement dateRoleChange / source
2024-10-17Group CEODavid Joyner succeeded Karen Lynch.
Primary source
2025-05-12CFOBrian Newman succeeded Thomas Cowhey; Cowhey initially served as an advisor.
Primary source
Sources, methods and limits

A collection readers can check.

Research window: January 2020–October 6, 2026. Earlier conduct is included when an action was announced during the window. Sources prioritize regulators, state procurement notices, SEC filings and company disclosures. Company award announcements are identified as such.

Subsidiaries are grouped under their parent, with the entity and business identified. Former subsidiaries are labeled. A source link appears with each record. Reporting an allegation is not a finding of liability.

  • Initial collection, not a complete inventory of every action, subsidiary or procurement from 2020–2026.
  • Payment confirmation and appeal dispositions remain incomplete; assessed or agreed amounts are not described as paid.
  • Earlier executive compensation extraction is incomplete: 2020 all companies; 2021 CVS; 2022 UnitedHealth. Earlier non-CEO pay and benefits remain to be extracted.
  • 2026 annual executive compensation is not yet reported for a completed fiscal year. Positions in the 2025 pay table reflect that disclosure, not a current leadership directory.
  • CVS detailed benefit breakdown remains to be extracted. All other compensation is not synonymous with benefits; it can include severance and other items.
  • No matched evidence establishes elimination and later reposting of the same positions. Need job title, requisition, duties, location, employing entity and dated notices/postings.
  • Initial contract collection is selective. No Humana contract loss is documented here; that is a coverage gap, not proof that none occurred.
  • Pharmacy, PBM, employer insurance and workers compensation actions are labeled separately from Medicaid / Medicare health-plan actions.
  • Unequal search coverage and company size prevent a defensible ranking of companies by the counts or amounts in this collection.

Analysis expresses questions and inferences from the listed records. It does not establish causation between executive pay, staffing changes and member outcomes.

The record at a glance

Historical base: October 6, 2026, with dated targeted updates in the source records. Coverage is incomplete and differs by company. These charts are not rankings of conduct. Zero means no qualifying record in this collection.

Financial action records

Audit recommendation0
Fine / penalty0
Proposed nonmonetary consent1
Repayment0
Settlement3

Counts by type in this collection. Assessments, agreements and audit recommendations are separate; these are not fines paid.

Explore data and primary sources

Contract outcome records

Awards / selections / renewals1
Losses / exits / nonrenewals1

Selections may be tentative. Counts are not contract values or market share.

Explore data and primary sources